HomeCompareMQBKY vs PFE

MQBKY vs PFE: Dividend Comparison 2026

MQBKY yields 2.90% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PFE wins by $24.3K in total portfolio value· pulled ahead in Year 9
10 years
MQBKY
MQBKY
● Live price
2.90%
Share price
$145.39
Annual div
$4.22
5Y div CAGR
4.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.3K
Annual income
$560.31
Full MQBKY calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — MQBKY vs PFE

📍 PFE pulled ahead of the other in Year 9

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMQBKYPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MQBKY + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MQBKY pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MQBKY
Annual income on $10K today (after 15% tax)
$246.44/yr
After 10yr DRIP, annual income (after tax)
$476.26/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, PFE beats the other by $21,843.64/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MQBKY + PFE for your $10,000?

MQBKY: 50%PFE: 50%
100% PFE50/50100% MQBKY
Portfolio after 10yr
$37.4K
Annual income
$13,409.52/yr
Blended yield
35.84%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

MQBKY
No analyst data
Price Target
$280.73
+93.1% upside vs current
Range: $280.73 — $280.73
Altman Z
0.5
Piotroski
4/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MQBKY buys
0
PFE buys
0
No recent congressional trades found for MQBKY or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMQBKYPFE
Forward yield2.90%6.13%
Annual dividend / share$4.22$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR4.4%13.2%
Portfolio after 10y$25.3K$49.6K
Annual income after 10y$560.31$26,258.71
Total dividends collected$4.2K$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst price target$280.73$27.50

Year-by-year: MQBKY vs PFE ($10,000, DRIP)

YearMQBKY PortfolioMQBKY Income/yrPFE PortfolioPFE Income/yrGap
1$11,003$302.68$9,153$693.39+$1.9KMQBKY
2$12,098$324.94$8,593$849.25+$3.5KMQBKY
3$13,293$348.60$8,336$1,066.78+$5.0KMQBKY
4$14,598$373.74$8,437$1,384.80+$6.2KMQBKY
5$16,020$400.44$9,013$1,875.40+$7.0KMQBKY
6$17,570$428.78$10,306$2,680.72+$7.3KMQBKY
7$19,259$458.84$12,820$4,101.38+$6.4KMQBKY
8$21,098$490.72$17,673$6,826.70+$3.4KMQBKY
9← crossover$23,099$524.51$27,543$12,591.86$4.4KPFE
10$25,276$560.31$49,560$26,258.71$24.3KPFE

MQBKY vs PFE: Complete Analysis 2026

MQBKYStock

Macquarie Group Limited provides diversified financial services in Australia, the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates through four segments: Macquarie Asset Management (MAM), Banking and Financial Services (BFS), Commodities and Global Markets (CGM), and Macquarie Capital. The MAM segment provides investment solutions to clients across various capabilities in private markets and public investments, including infrastructure, green investments, agriculture and natural assets, real estate, private credit, asset finance, equities, fixed income, and multi-asset solutions. The BFS segment offers personal banking products comprising home loans, car loans, transaction and savings accounts, and credit cards; and wrap platform and cash management, financial advisory, private banking, and stockbroking services, as well as investment and superannuation products. It also provides deposit, lending, and payment solutions and services to business clients, such as sole practitioners to corporate professional firms. The CGM segment provides risk management, lending and financing, capital solutions, market access, and physical execution and logistics to corporate and institutional clients; and specialist finance and asset management solutions. The Macquarie Capital segment provides advisory and capital raising services. It is also involved in facilitation, and development and investment in infrastructure and energy projects and companies; and trading of fixed income, equities, foreign exchange, and commodities, as well as provides broking services, corporate and structured finance, and leasing and underwriting services. Further, the company engages in the distribution and management of funds and wealth management products. Macquarie Group Limited was founded in 1969 and is headquartered in Sydney, Australia.

Full MQBKY Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this MQBKY vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MQBKY vs SCHDMQBKY vs JEPIMQBKY vs OMQBKY vs KOMQBKY vs MAINMQBKY vs JNJMQBKY vs MRKMQBKY vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.